Fluorescent protein variant for observing cell damage, and drug toxicity evaluation method using same
Fluorescent protein variants cleaved by caspase 3 or 7, integrated into cell lines via AAVS1 vectors, address the limitations of existing apoptosis monitoring and drug toxicity evaluation methods by enabling real-time apoptosis progression and toxicity assessment through fluorescence changes.
Patent Information
- Application Number
- PCT/KR2023/006381
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2023-05-10
- Publication Date
- 2024-11-14
AI Technical Summary
Current methods for monitoring apoptosis progression in real-time and evaluating drug toxicity are limited by the difficulty in achieving stable expression in vitro and in vivo, and they cannot confirm the progression of apoptosis effectively.
Development of fluorescent protein variants with an amino acid sequence cleaved by caspase 3 or 7, specifically in the hinge region, which allows for real-time monitoring of cell damage by changing fluorescence expression, using a recombinant vector system like AAVS1 to introduce these variants into cell lines, enabling the evaluation of drug toxicity.
The fluorescent protein variants enable real-time confirmation of apoptosis progression and drug toxicity evaluation by changing fluorescence levels in response to caspase activity, providing a stable and effective method for monitoring cell damage and drug effects.
Smart Images

Figure KR2023006381_14112024_PF_FP_ABST
Abstract
Description
Fluorescent protein variants for observing cell damage and drug toxicity evaluation methods using the same
[0001] The present invention relates to a fluorescent protein variant for observing cell damage, a gene encoding the same, a vector system including the same, a transformed cell using the same, and a use thereof.
[0002] Known mechanisms of cell death include necrosis and apoptosis. Unlike necrosis, which can be considered a type of "accidental death" caused by external stimuli, apoptosis, a genetically programmed, selective cell death, is known to occur during development and differentiation to eliminate unnecessary components or when cells are severely damaged beyond repair.
[0003] Apoptosis plays a crucial role in maintaining the development and homeostasis of living organisms and can be divided into the extrinsic pathway and the intrinsic pathway. Furthermore, the two pathways are interconnected, so substances that react in one pathway can affect the other pathway (S Elmore et al., Toxicologic Pathology, 35:495-516, 2007).
[0004] Apoptosis is induced by the cleavage of various substrates through the activation of caspase enzymes by protein cascade reactions. In particular, among caspase enzymes, caspase 3 and caspase 7 are cysteine-aspartic acid proteases that are known to recognize and cleave specific peptide sequences (Asp-Glu-Val-Asp-Gly; DEVDG) (Thornberry, NA et al., J. Biol. Chem, 272:17907, 1997).
[0005] Taking advantage of these characteristics of caspase 3 and caspase 7, many methods have been developed to detect the degree of caspase activation and the progression of apoptosis by incorporating the DEVDG sequence into various probes. However, existing methods can only detect the presence or absence of caspase activation, and cannot detect the progression of apoptosis in real time. In addition, stable expression in vitro and in vivo is difficult, making it difficult to introduce into cell lines and animal models. Therefore, research is needed to develop a method that can stably express in vitro and in vivo and monitor the progression of apoptosis in real time.
[0006] Accordingly, the present inventors completed the present invention by producing a fluorescent protein mutant by mutating some of the amino acid sequences of the hinge region, which do not affect the function of the fluorescent protein, to DEVDG, and introducing an AAVS1 vector containing a gene encoding the fluorescent protein mutant into a cell line and confirming that fluorescence expression changes due to caspase 3 or caspase 7 activity.
[0007] To achieve the above object, one aspect of the present invention provides a fluorescent protein (FP) variant whose fluorescence expression changes in damaged or dead cells, wherein the fluorescent protein variant includes an amino acid sequence that is cleaved by caspase in a hinge region that does not affect the function of the fluorescent protein.
[0008] Another aspect of the present invention provides a polynucleotide encoding the fluorescent protein variant.
[0009] Another aspect of the present invention provides a recombinant vector comprising the polynucleotide.
[0010] Another aspect of the present invention provides a composition for detecting cell damage or apoptosis comprising the fluorescent protein variant, polynucleotide, or recombinant vector as an active ingredient.
[0011] Another aspect of the present invention provides a transformed cell transformed with the recombinant vector.
[0012] Another aspect of the present invention provides a method for evaluating drug toxicity, comprising: i) treating a sample in the transformed cell; ii) measuring fluorescence expression of the cell treated with the sample; and iii) determining that the sample is toxic to the cell if the fluorescence expression changes.
[0013] The transformed cells according to the present invention can monitor cell damage in real time by monitoring the level of fluorescence expression that changes depending on the activity of caspase 3 or caspase 7. Furthermore, the transformed cells according to the present invention can be used to evaluate the toxicity of various drugs. Therefore, the present invention can be usefully applied to cell damage research or drug development.
[0014] Figure 1 shows the hydrophilic portion of the sequence of green fluorescent protein analyzed using the Kyte-Doolittle scale (A) and the Hopp-Woods scale (B).
[0015] Figure 2 shows the #1 site mutation portion of the green fluorescent protein, indicated by the sequence in the box and the black area.
[0016] Figure 3 shows the #2 position mutation portion of the green fluorescent protein, indicated by the sequence in the box and the black area.
[0017] Figure 4 shows the #3 position mutation of the green fluorescent protein, indicated by the sequence in the box and the black area.
[0018] Figure 5 shows the #4 position mutation of the green fluorescent protein, indicated by the sequence in the box and the black area.
[0019] Figure 6 shows the mutation portions at positions #1 to #4 of the green fluorescent protein in the base sequence.
[0020] Figure 7 is a schematic diagram illustrating the process for producing a pCAGGS vector into which base sequences encoding green fluorescent protein #1 to #4 variants have been inserted.
[0021] Figure 8 shows a schematic diagram of the pCAGGS vector (4833 bp).
[0022] Figure 9 is a schematic diagram of a pCAGGS vector into which a base sequence encoding a green fluorescent protein #1 variant has been inserted.
[0023] Figure 10 is a schematic diagram of a pCAGGS vector into which a base sequence encoding a green fluorescent protein #2 variant has been inserted.
[0024] Figure 11 is a schematic diagram of a pCAGGS vector into which a base sequence encoding a green fluorescent protein #3 variant has been inserted.
[0025] Figure 12 is a schematic diagram of a pCAGGS vector into which a base sequence encoding a green fluorescent protein #4 variant has been inserted.
[0026] Figure 13 shows the expression of green fluorescent protein after introducing a pCAGGS vector into HEK293 cells, into which a base sequence encoding any one of green fluorescent protein #1 to #4 variants was inserted.
[0027] Figure 14 is a schematic diagram of the manufacturing process of the AAVS1 SA-EGFP #4 site mutation-2A-puro-pA donor vector.
[0028] Figure 15 shows a schematic diagram of the AAVS1 SA-2A-puro-pA donor vector.
[0029] Figure 16 shows a schematic diagram of the AAVS1 SA-EGFP #4 site mutation-2A-puro-pA donor vector.
[0030] Figure 17 shows the process of establishing the AAVS1-EGFP #4 (DEVDG) 293 cell line by introducing the AAVS1 SA-EGFP #4 site mutation-2A-puro-pA donor vector into HEK293 cells.
[0031] Figure 18 shows a schematic diagram of the introduction of the AAVS1 SA-EGFP #4 site mutation-2A-puro-pA donor vector and the primer positions for genotyping PCR.
[0032] Figure 19 shows the results of genotyping PCR performed on AAVS1-EGFP #4 (DEVDG) 293 cell line, in cases where the vector was not inserted (knock-in; KI) (WT), in cases where the vector was inserted into one allele (Heterogeneous genotype) (#3), and in cases where the vector was inserted into both alleles (Homogenous genotype) (#8).
[0033] Figure 20 shows the results observed under a fluorescence microscope after treating AAVS1-EGFP #4-3 (He: heterogeneous genotype) cells and AAVS1-EGFP #4-8 (Ho: homogeneous genotype) cells with Staurosporin (STA) for 48 hours.
[0034] Figure 21 shows the results of flow cytometry analysis after treating AAVS1-EGFP #4-3 (He: heterogeneous genotype) cells and AAVS1-EGFP #4-8 (Ho: homogeneous genotype) cells with 1 μM staurosporine for 48 hours.
[0035] Figure 22 shows the results of analysis using Semi RT-PCR after treating AAVS1-EGFP #4-3 (He: heterogeneous genotype) cells and AAVS1-EGFP #4-8 (Ho: homogeneous genotype) cells with staurosporine at a concentration of 1 μM for 48 hours.
[0036] Figure 23 shows the results observed under a fluorescence microscope after treating AAVS1-EGFP #4-8 (Ho: homo genotype) cells with staurosporine at concentrations of 0.1 μM, 0.25 μM, 0.5 μM, and 1 μM for 48 hours.
[0037] Figure 24 shows the results of flow cytometry analysis after treating AAVS1-EGFP #4-8 (Ho: homo genotype) cells with staurosporine at concentrations of 0.1 μM, 0.25 μM, 0.5 μM, and 1 μM for 48 hours.
[0038] Figure 25 shows the results of Western blot analysis after treating AAVS1-EGFP #4-8 (Ho: homo genotype) cells with staurosporine at concentrations of 0.1 μM, 0.25 μM, 0.5 μM, and 1 μM for 48 hours.
[0039] Figure 26 shows the results observed using TUNEL staining and DAPI staining after treating AAVS1-EGFP #4-8 (Ho: homo genotype) cells with staurosporine at concentrations of 0.5 μM and 1 μM for 48 hours.
[0040] Figure 27 shows the target sequence #4 in blue fluorescent protein (EBFP), cyan fluorescent protein (ECFP), green fluorescent protein (EGFP), and yellow fluorescent protein (EYFP) on the base sequence.
[0041] Figure 28 shows the #4 position mutation portion of the blue fluorescent protein marked in red.
[0042] Figure 29 shows the #4 position mutation portion of the yellow fluorescent protein marked in red.
[0043] Figure 30 shows the #4 position mutation portion of the cyan fluorescent protein, highlighted in red.
[0044] Figure 31 is a schematic diagram of a pCAGGS vector into which a base sequence encoding a wild-type blue fluorescent protein has been inserted.
[0045] Figure 32 is a schematic diagram of a pCAGGS vector into which a base sequence encoding a blue fluorescent protein #4 variant has been inserted.
[0046] Figure 33 shows the expression of blue fluorescent protein after introducing a pCAGGS vector into HEK293 cells, into which a base sequence encoding blue fluorescent protein #4 variant was inserted.
[0047] Figure 34 shows the expression of green fluorescent protein confirmed by fluorescence microscopy after introducing the pCAGGS-EGFP #4 vector into HEK293 cells.
[0048] Figure 35 shows the expression of green fluorescent protein confirmed by flow cytometry after introducing the pCAGGS-EGFP #4 vector into HEK293 cells.
[0049] Figure 36 shows the results observed under a fluorescence microscope after introducing a pCAGFP vector into HEK293 cells and treating them with staurosporine at a concentration of 1 μM for 48 hours.
[0050] Figure 37 shows the results of flow cytometry analysis after introducing the pCAGFP vector into HEK293 cells and treating them with staurosporine at a concentration of 1 μM for 48 hours.
[0051] Figure 38 shows real-time imaging fluorescence microscopy of 293 AAVS1-EGFP #4-8 cell line (A) apoptosis-induced group (staurosporine treatment; +STA, 1 μM) at 30-minute intervals for 48 hours.
[0052] And (B) real-time cell damage monitoring of the control group (staurosporine-untreated; -STA) was confirmed.
[0053] Figure 39 shows a fluorescent photograph and genotyping analysis of a cell line constructed by introducing the AAVS1-EGFP #4 vector into the colon cancer cell line SW480. In the genotyping analysis, #3, #4, #6, #9, #13, #15, and #17 are heterozygous, and #10 is wild type.
[0054] Figure 40 shows a fluorescence photograph and genotyping analysis of a cell line constructed by introducing the AAVS1-EGFP #4 vector into the colon cancer cell line SW620. In the genotyping analysis, #2, #3, #6, #7, #8, #9, #10, #13, #14, #24, #27, #28, #35, #36, #37 and #40 are heterozygous.
[0055] Figure 41 shows the fluorescent photograph and genotyping analysis of cell lines constructed by introducing the AAVS1-EGFP #4 vector into the colon cancer cell line HCT 116. In the genotyping analysis, #1, #3, #4, #5, #6, #10, #13, #14, #16, #17, #19, #20, #21, #22, #23, #24, #26, #29, #31, #34, #37 and #38 are homozygous, #2, #7, #8, #27, #28, #30, #32, #33, #35 and #36 are heterozygous, and #11 and #15 are wild type.
[0056] Figure 42 is a fluorescence photograph taken 24 and 48 hours after treatment with 1 μM staurosporine in the SW480 AAVS1-EGFP#4 cell line, and the graph at the bottom shows the relative fluorescence intensity.
[0057] Figure 43 is a fluorescence photograph taken 24 and 48 hours after treatment with 1 μM staurosporine in the SW620 AAVS1-EGFP#4 cell line, and the graph at the bottom shows the relative fluorescence intensity.
[0058] Hereinafter, the present invention will be described in detail.
[0059] One aspect of the present invention provides a fluorescent protein (FP) variant whose fluorescence expression is changed in damaged or dead cells, wherein the fluorescent protein variant includes an amino acid sequence that is cleaved by a caspase in a hinge region that does not affect the function of the fluorescent protein.
[0060] The term "fluorescent protein" in the present invention refers to a protein that fluoresces in a specific color within a living body and allows for the observation of the function of proteins within the body. Specifically, fluorescent proteins can be attached to genes or probes and injected into cells, allowing for the observation of intracellular gene expression, protein synthesis, and cell growth processes.
[0061] The fluorescent protein may be Green Fluorescent Protein (GFP), Blue Fluorescent Protein (BFP), Yellow Fluorescent Protein (YFP), or Cyan Fluorescent Protein (CFP), and may be Enhanced Green Fluorescent Protein (EGFP), Enhanced Blue Fluorescent Protein (EBFP), Enhanced Yellow Fluorescent Protein (EYFP), or Enhanced Cyan Fluorescent Protein (ECFP), but is not limited thereto, and any protein exhibiting a similar function may be included in the category.
[0062] The term "variant" of the present invention encompasses fragments and polypeptides having altered amino acid sequences due to amino acid substitutions, deletions, or insertions. Variants may be naturally occurring or artificially generated, and artificial variants may be generated using mutagenesis techniques known in the art. Furthermore, variant polypeptides may include conservative or non-conservative amino acid substitutions, deletions, or additions.
[0063] The fluorescent protein variant may include an amino acid sequence that is cleaved by a caspase. Specifically, the amino acid sequence that is cleaved by a caspase may be aspartic acid-glutamic acid-valine-aspartic acid-glycine (DEVDG) or aspartic acid-glutamic acid-valine-aspartic acid (DEVD), and may be cleaved by caspase 3 or 7. In one embodiment of the present invention, a fluorescent protein variant that is cleaved by caspase 3 or caspase 7 was prepared by replacing a part of the amino acid sequence of the hinge region, which does not affect the function of the fluorescent protein, in the amino acid sequence of the wild-type fluorescent protein with the DEVDG sequence, which is an amino acid sequence that is cleaved by caspase 3 or caspase 7. An amino acid sequence that includes the part substituted in the present invention among the amino acid sequences of the wild-type fluorescent protein and has additional substitutions, deletions, or additions is also included in the present invention.
[0064] In the case of the recombinant reporter system previously used to confirm the activity of caspase 3 or caspase 7, there was a disadvantage in that the length of the gene encoding the wild-type fluorescent protein used as the reporter was lengthened by adding the DEVDG sequence to the wild-type fluorescent protein or using a linker. In the case of the present invention, in order to minimize the modification of the wild-type fluorescent protein, a position having a sequence similar to DEVDG was selected among the sequences of the wild-type fluorescent protein and substituted with DEVDG. Therefore, the fluorescent protein mutant produced by the method of the present invention has an amino acid sequence recognized and cleaved by caspase 3 or caspase 7, while maintaining the gene length of the wild type, and has the advantage of not requiring a complex structure since the loss of the fluorescent protein can be confirmed by cleavage without the need for a separate base sequence or blocker / quencher.
[0065] The term "caspase" in the present invention refers to a type of protease that cleaves a specific region of a target protein, thereby causing apoptosis. Specifically, caspases 8, 9, and 10 can act in the early stages of cell damage to activate the caspase cascade, while caspases 2, 3, 6, and 7 can ultimately cause apoptosis by degrading DNA and proteins.
[0066] The term "hinge region" of the present invention refers to a region other than the α-helix and β-sheet regions that are considered to be related to the function of a fluorescent protein, and corresponds to, for example, a Bond outlier region. The "hinge region that does not affect the function of a fluorescent protein" refers to a region in which mutation of the amino acid sequence of the region does not significantly affect the function of the protein, and it can be understood that a loss of 40% or less of the fluorescent protein function due to mutation does not significantly affect it.
[0067] In one embodiment of the present invention, when producing a mutant of a fluorescent protein, the position to be mutated is a hinge region other than a region that affects the function of the fluorescent protein, such as the α-helix and β-sheet of the fluorescent protein.
[0068] In one embodiment of the present invention, a portion of the amino acid sequence of the hinge region may be substituted to include an amino acid sequence that is cleaved by a caspase.
[0069] By replacing the existing sequence in the hinge region, the wild-type gene length can be maintained, minimizing the modification of the fluorescent protein, and it is advantageous in that it does not require a separate base sequence or blocker / quencher.
[0070] The fluorescent protein variant may be one in which the asparagine-isoleucine-glutamic acid (NIE) sequence in the amino acid sequence of the pre-mutation fluorescent protein is replaced with an aspartic acid-glutamic acid-valine (DEV) sequence. In this case, the asparagine-isoleucine-glutamic acid (NIE) sequence may be the 171st to 173rd amino acids of the amino acid sequence represented by SEQ ID NO: 1, the 171st to 173rd amino acids of the amino acid sequence represented by SEQ ID NO: 33, the 172nd to 174th amino acids of the amino acid sequence represented by SEQ ID NO: 34, or the 171st to 173rd amino acids of the amino acid sequence represented by SEQ ID NO: 35.
[0071] Accordingly, the fluorescent protein variant may be one in which the 171st to 173rd amino acids of the amino acid sequence represented by sequence number 1, namely asparagine (N), isoleucine (I), and glutamic acid (E), are substituted with aspartic acid (D), glutamic acid (E), and valine (V), respectively.
[0072] In addition, the fluorescent protein variant may be one in which the 171st to 173rd amino acids of the amino acid sequence represented by SEQ ID NO: 33, namely asparagine (N), isoleucine (I), and glutamic acid (E), are substituted with aspartic acid (D), glutamic acid (E), and valine (V), respectively.
[0073] In addition, the fluorescent protein variant may be one in which the 172nd to 174th amino acids of the amino acid sequence represented by SEQ ID NO: 34, namely asparagine (N), isoleucine (I), and glutamic acid (E), are substituted with aspartic acid (D), glutamic acid (E), and valine (V), respectively.
[0074] In addition, the fluorescent protein variant may be one in which the 171st to 173rd amino acids of the amino acid sequence represented by SEQ ID NO: 35, namely asparagine (N), isoleucine (I), and glutamic acid (E), are substituted with aspartic acid (D), glutamic acid (E), and valine (V), respectively.
[0075] In one embodiment of the present invention, a cell line expressing a fluorescent protein variant in which a portion of the hinge region of the fluorescent protein is mutated to a DEVDG sequence that is cleaved by caspase 3 or caspase 7 was prepared, and it was confirmed that the cell line uniformly expressed fluorescence, and that such fluorescence expression was significantly reduced by cell damage (Example 8). On the other hand, in the case of a fluorescent protein variant prepared by inserting a DEVDG sequence between the C-terminal region of the fluorescent protein and a quenching peptide, it was predicted that cells expressing the fluorescent protein variant should exhibit fluorescence when cleaved by cell damage (i.e., by caspase 3 or 7), but it was confirmed that fluorescence was exhibited even without cell damage, and that fluorescence expression was not uniformly displayed in all cells after cell damage (Comparative Example 2). Therefore, mutating the hinge region of a fluorescent protein is more effective in detecting fluorescence expression due to cell damage than mutating the DEVDG sequence in the C-terminal region of a previously known fluorescent protein.
[0076] Another aspect of the present invention provides a polynucleotide encoding the fluorescent protein.
[0077] The polynucleotide may be a nucleotide sequence represented by SEQ ID NO: 14. Specifically, a nucleotide sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the nucleotide sequence represented by SEQ ID NO: 14 is also included in the present invention. In addition, the polynucleotide may be a nucleotide sequence represented by SEQ ID NO: 39. Specifically, a nucleotide sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the nucleotide sequence represented by SEQ ID NO: 39 is also included in the present invention. In addition, the polynucleotide may be a nucleotide sequence represented by SEQ ID NO: 40. Specifically, a nucleotide sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the nucleotide sequence represented by SEQ ID NO: 40 is also encompassed by the present invention. In addition, the polynucleotide may be a nucleotide sequence represented by SEQ ID NO: 41. Specifically, a nucleotide sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the nucleotide sequence represented by SEQ ID NO: 41 is also encompassed by the present invention.
[0078] Another aspect of the present invention provides a recombinant vector comprising a polynucleotide.
[0079] The above vector may be an adeno-associated virus integration site 1 (AAVS1) vector. The AAVS1 vector targets the integration of the insert DNA into AAVS1, a safe harbor of the human genome located on human chromosome 19. Gene introduction targeting AAVS1 has been confirmed to be a safe site that does not affect the phenotype of the cell, and is known to enable stable and sustained expression of the introduced gene in many cell types, including embryonic stem cells. In one embodiment of the present invention, it was confirmed that a cell line exhibiting uniform fluorescence expression could be produced using the AAVS1 SA-2A-puro-pA donor (#22075, Addgene) vector (Example 8). On the other hand, it was confirmed that it was difficult to establish a cell line exhibiting uniform fluorescence expression when a vector that does not target the AAVS1 locus was used (Comparative Example 1). Therefore, to establish a cell line in which fluorescence expression is uniform, it is essential to use a vector that allows the gene encoding the fluorescent protein variant to be inserted into the AAVS1 locus.
[0080] The above recombinant vector may additionally include an antibiotic resistance gene. The antibiotic resistance gene may be a resistance gene for one or more antibiotics selected from the group consisting of penicillin, streptomycin, neomycin, puromycin, and hygromycin, and specifically, the antibiotic resistance gene may be a resistance gene for puromycin.
[0081] Another aspect of the present invention provides a composition for detecting cell damage or apoptosis comprising the fluorescent protein variant, polynucleotide, or recombinant vector as an active ingredient.
[0082] The composition may comprise the fluorescent protein variant, polynucleotide, or recombinant vector alone or may further comprise one or more pharmaceutically acceptable carriers.
[0083] Another aspect of the present invention provides a transformed cell transformed with the recombinant vector.
[0084] The method for transforming the recombinant vector into a cell can utilize a method known in the art, and for example, transient transfection, microinjection, transduction, cell fusion, calcium phosphate precipitation, liposome-mediated transfection, DEAE dextran-mediated transfection, polybrene-mediated transfection, electroporation, gene gun, or other known methods for introducing nucleic acids into cells can be used, but are not limited thereto.
[0085] In addition, the recombinant vector can be inserted into one allele of a cell to construct a heterogeneous transformed cell or a homogeneous transformed cell inserted into both alleles. In one embodiment of the present invention, the AAVS1-EGFP # 4 vector is introduced into HEK293 cells, cultured, and then first selected with puromycin. Then, cells expressing only GFP are secondarily selected using FACS. After performing genotyping PCR on the selected cells, the band sizes of the samples are compared to distinguish wild type, heterogeneous, and homogeneous cells, thereby introducing the recombinant vector to produce heterogeneous or homogeneous cells.
[0086] Methods for determining whether a recombinant vector has been introduced into the transformed cells may be molecular biological assays or biochemical assays known in the art. Molecular biological assays include Southern and Northern blotting, RT-PCR, and PCR, while biochemical assays include detecting the presence or absence of specific proteins / peptides by immunological methods (e.g., ELISA and Western blot). In one embodiment of the present invention, genotyping PCR was performed to confirm introduction of the vector into the cells.
[0087] The method may additionally include a step of isolating transformed cells expressing a fluorescent protein.
[0088] The method for isolating the transformed cells expressing the fluorescent protein can isolate the transformed cells expressing the fluorescent protein through a process of first selecting cells resistant to the antibiotic by treating them with antibiotics. In addition, the method for isolating the human cells expressing the fluorescent protein can isolate the transformed cells expressing the fluorescent protein through a process of selecting cells expressing the fluorescent protein using FACS (Fluorescence-activated Cell Sorting). Furthermore, the method for isolating the human cells expressing the fluorescent protein can isolate the transformed cells expressing the fluorescent protein through a process of first selecting human cells resistant to the antibiotic by treating them with antibiotics, and then selecting cells expressing the fluorescent protein using FACS.
[0089] In one embodiment of the present invention, HEK293 cells were seeded in a 100 mm culture dish, and then the cells were transfected with 5 μg of AAVS1-EGFP #4 vector. After 3 days, when the cells were cultured to about 90% confluent, 3 μl of puromycin (#A11138-03, gibco) was treated in 10 ml of culture medium to perform puromycin selection. After 14 days, when the cells were cultured to about 70% to 80% confluent, only cells expressing only green fluorescent protein were secondarily selected using FACS (Fluorescence-activated Cell Sorting).
[0090] Another aspect of the present invention provides a method for assessing drug toxicity, comprising: i) treating a sample in the transformed cell; ii) measuring fluorescence expression in the cell treated with the sample; and iii) determining that the sample is toxic to the cell if the fluorescence expression changes. In this case, the transformed cell is the same as described above.
[0091] The method for measuring the fluorescence expression of cells in step ii) above can be confirmed in real time using molecular biological assays known in the art, such as Southern and Northern blotting, RT-PCR, and PCR; biochemical assays, such as fluorescence microscopy; and immunological methods (e.g., FACS, ELISA, and Western blot). In one embodiment of the present invention, the expression level of the fluorescent protein was confirmed in real time using fluorescence microscopy and flow cytometry (FACS).
[0092] The change in fluorescence expression in step iii) above may be due to the activity of caspase 3 or caspase 7.
[0093] The drug toxicity evaluation method of step iii) above measures the level of change in the expression of a fluorescent protein by treating a sample on a transformed cell, and if the level of expression of the fluorescent protein decreases, the sample can be judged to be toxic to the cell.
[0094] Hereinafter, the present invention will be described in more detail with reference to the following examples. However, the following examples are intended only to illustrate the present invention, and the scope of the present invention is not limited to these examples.
[0095] I. Preparation of green fluorescent protein variant vector system
[0096] To enable real-time monitoring of the expression of green fluorescent protein by the activity of caspase 3 or caspase 7 in cells, a portion of the amino acid sequence of the hinge region, which does not affect the function of green fluorescent protein, was mutated to DEVDG, and an AAVS1 vector containing a gene encoding such a green fluorescent protein mutant was prepared.
[0097] Example 1. Selection of target amino acid candidates within green fluorescent protein for production of green fluorescent protein variants.
[0098] In order to predict the hydrophilic amino acid portion that can bind to a drug among the amino acid sequence (SEQ ID NO. 1) of Enhanced Green Fluorescent Protein (EGFP), the amino acid sequence (MVSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLPVPWPTLVTTLTYGVQCFSRYPDHMKQHDFFKSAMPEGYVQERTIFFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNYNSHNVYIMADKQKNGIKVNFKIRHNIEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSALSKDPNEKRDHMVLLEFVTAAGITLGMDELYK) of the EGFP gene (SEQ ID NO. 2) used in the present invention was input into the ExPASy ProtScale site (https: / / web.expasy.org / protscale / ). Amino acid sequences were analyzed using the Kyte-Doolittle scale and the Hopp-Woods scale (Fig. 1). In this case, a positive number on the Kyte-Doolittle scale indicates hydrophobicity, a negative number indicates hydrophilicity, and a positive number on the Hopp-Woods scale indicates hydrophilicity.
[0099] In order to select an amino acid sequence that can be mutated to DEVDG among the amino acid regions predicted to be hydrophilic through the above process, each hydrophilic amino acid region was analyzed using the information on the RCSB PDB site (https: / / www.rcsb.org / structure / 4EUL). Specifically, among the hydrophilic amino acid regions, the Bond outlier region that does not affect the properties and structure of green fluorescent protein, such as hydrophilicity, polarity, buriedness, accessibility, rotation, flexibility, and bending, was selected. The Bond outlier region is the hinge region, which is a region other than the α-helix and β-sheet regions of the protein structure, and is understood to not affect the function of the protein. At this time, in order to minimize mutations in the wild-type enhanced green fluorescent protein (EGFP WT), the region with an amino acid sequence similar to DEVDG was selected as a target. The amino acid sequences of the selected target candidate sequences #1 to #4 and the positions of the target candidate sequences #1 to #4 on the three-dimensional structure of EGFP are indicated by the sequences in the boxes and the black areas in Figures 2 to 5, respectively.
[0100] Example 2. DEVDG mutation of target amino acid
[0101] The base sequence positions of EGFP for target candidates #1, #2, #3, and #4 selected through Example 1 are shown in Figure 6.
[0102] The base sequences of the EGFP target candidates #1 to #4 (Table 1) were mutated using the Bioneer gene synthesis service. Target candidate #1 was mutated to the GACGAGGTCGACGGC base sequence (SEQ ID NO: 11), and target candidates #2 to #4 were mutated to the GACGAGGTGGACGGC base sequence (SEQ ID NO: 12), so that the amino acid sequences encoded by these base sequences were all DEVDG (SEQ ID NO: 13). The entire base sequence of the EGFP #4 mutant is described in SEQ ID NO: 14.
[0103] Target candidate sequence number #1 Base sequence TTCAAGGACGACGGC3 Amino acid sequence FKDDG4 #2 Base sequence GCCGAGGTGAAGTTC5 Amino acid sequence AEVKF6 #3 Base sequence TTCAAGGAGGACGGC7 Amino acid sequence FKEDG8 #4 Base sequence AACATCGAGGACGGC9 Amino acid sequence NIEDG10
[0104] Example 3. Construction of a pCAGGS vector containing a gene encoding a green fluorescent protein variant.
[0105] Enhanced green fluorescent protein mutant genes, each of which had its target candidate sequences #1 to #4 of the wild-type enhanced green fluorescent protein (EGFP) mutated, were cloned into the pCAGGS vector (Fig. 7).
[0106] 3-1. Insert DNA preparation
[0107] In-Fusion PCR was performed using wild-type EGFP and EGFP #1 to #4 site mutation genes as templates using TaKaRa Ex Taq™ (#HRR001A, TAKARA) under the conditions in Table 2 below. The primers used in In-Fusion PCR are shown in Table 3 below. By using the primers in Table 3, restriction enzyme (BglII) sites were created in wild-type EGFP and EGFP #1 to #4 site mutation genes.
[0108] In-Fusion PCR Temperature Time Step 1: 98℃ 2 minutes Step 2: 35 cycles 98℃ 62℃ 72℃ 10 seconds 10 seconds 10 seconds Step 3: 72℃ 5 minutes Step 1: Initial denaturation, Step 2: Amplification, Step 3: Final elongation
[0109] Primer bp sequence Sequence number pCAG-EGFP infusion F752bpAATACCACTGAGATCTATGGTGAGCAAGGGCGAGG15 pCAG-EGFP infusion R752bpAGAGGGAAAAAGATCTTTACTTGTACAGCTCGTCCATGCC16
[0110] Electrophoresis was performed on the amplified PCR product, and a band corresponding to the target size (752 bp) was recovered from the loaded sample through electrophoresis, after which DNA was extracted using Geneclean® turbo kit (#111102-600, MP).
[0111] 3-2. Vector preparation
[0112] A BglII site was created in the MSC (multiple cloning site) of the pCAGGS vector, and the insert DNA was cut with BglII (#R0144L, NEB) restriction enzyme when inserted and used as a backbone vector (Fig. 8).
[0113] 3-3. Production of wild-type EGFP and EGFP #1-#4 position mutant expression vectors by ligating insert DNA into the vector
[0114] The insert DNA prepared in Example 3-1 was ligated into the vector prepared in Example 3-2 using the In-Fusion® HD Cloning Kit (#639649, TAKARA) to prepare wild-type EGFP and EGFP #1 to #4 position mutant expression vectors. The pCAGGS vectors prepared individually for each insert are shown in Figures 9 to 12.
[0115] 3-4. Transformation
[0116] The pCAGGS vector, in which the genes of the EGFP wild type and mutants were each inserted, was transformed into HIT Competent Cells-DH5alpha High 108 (#RH618, RBC) on an LB broth plate.
[0117] Example 4. Verification of fluorescence expression by target sequence
[0118] The expression of the green fluorescent protein variant of each pCAGGS vector prepared in Example 3 was verified.
[0119] As a result of confirming the expression of the green fluorescent protein mutant in the cell lines into which each pCAGGS vector was introduced through a fluorescence microscope, it was confirmed that the mutant green fluorescent protein was expressed normally in the cell lines into which the pCAGGS vector containing the EGFP #4 mutant gene was introduced, and it was confirmed that the green fluorescent protein mutant was hardly expressed in the cell lines into which other pCAGGS vectors were introduced (Fig. 13).
[0120] Example 5. Production of an AAVS1 vector containing a gene encoding a green fluorescent protein variant.
[0121] The EGFP #4 mutant gene verified through Example 4 was cloned into the AAVS1 SA-2A-puro-pA donor vector (#22075, Addgene) (Fig. 14).
[0122] 5-1. Insert DNA preparation
[0123] In-Fusion PCR was performed using the EGFP #4 mutant gene as a template and TaKaRa Ex Taq™ (#HRR001A, TAKARA) under the conditions shown in Table 4 below. The primers used in In-Fusion PCR are shown in Table 5 below. By using the primers in Table 5, a restriction enzyme (BglII) site was created in the EGFP #4 mutant gene.
[0124] In-Fusion PCR Temperature Time Step 1: 98℃ 2 minutes Step 2: 35 cycles 98℃ 62℃ 78℃ 10 seconds 10 seconds 10 seconds Step 3: 72℃ 5 minutes Step 1: Initial denaturation, Step 2: Amplification, Step 3: Final elongation
[0125] Primer bp sequence sequence number EGFP mutation infusion F749bpGGGCCTCGAGAGATCTATGGTGAGCAAGGGCGAGG17 EGFP mutation infusion R749bpCTCCGCTGCCAGATCTCTTGTACAGCTCGTCCATGCC18
[0126] Electrophoresis was performed on the amplified PCR product above, and a band corresponding to the target size (749 bp) was recovered from the loaded sample through electrophoresis, after which DNA was extracted using the Geneclean® turbo kit.
[0127] 5-2. Production of EGFP #4 mutant expression vector by ligating insert DNA into the vector
[0128] The extracted 749 bp DNA fragment was used as insert DNA, and the AAVS1 SA-2A-puro-pA donor vector was digested with BglII restriction enzyme and used as a backbone vector. At this time, ligation of the insert DNA and the backbone vector was performed using the In-Fusion® HD Cloning Kit. The manufactured AAVS1 vector was named AAVS1 SA-EGFP #4 site mutation-2A-puro-pA donor (hereinafter referred to as 'AAVS1-EGFP #4 vector').
[0129] 5-3. Transformation
[0130] The HIT Competent Cells-DH5alpha High 108 (#RH618, RBC) cell line was transformed in an LB broth plate with the AAVS1-EGFP #4 vector prepared in Example 5-2.
[0131] Example 6. Construction of a transformed cell line introducing the AAVS1 SA-EGFP #4 vector.
[0132] The AAVS1 SA-EGFP #4 vector prepared in Example 5 was introduced into HEK293 cells derived from human embryonic kidney to establish a transformed cell line (Fig. 17).
[0133] First, HEK293 cells were seeded on 100 mm culture dishes, and when the cells were cultured at 70% to 80% confluent, 5 μg of AAVS1-EGFP #4 vector was introduced into the cells using the 4D-Nucleofector™ device according to the SF kit, CM-130 program, and manufacturer's manual. After 3 days, when the cells were cultured at 90% confluent, puromycin selection was performed by adding 3 μl of puromycin (#A11138-03, gibco) to 10 ml of culture medium. After 14 days, when the cells were cultured again to about 70% to 80% confluent, cells expressing green fluorescent protein were selected for the second time using fluorescence-activated cell sorting (FACS), and the selected single cells were seeded in 96-well plates, cultured, and then subcultured in 24-well plates to establish transformed cell lines.
[0134] The transformed cell line constructed through the above process was named AAVS1-EGFP #4 (DEVDG) 293 cell line, and a cell line in which the AAVS1-EGFP #4 vector was inserted into one allele and a cell line in which the AAVS1-EGFP #4 vector was inserted into both alleles were constructed through the same process as above.
[0135] Example 7. Genotyping of transformed cell lines
[0136] To confirm whether the AAVS1-EGFP #4 vector was correctly inserted into the HEK293 cells, genomic DNA was extracted from cells in which EGFP fluorescence was expressed and maintained through a fluorescence microscope among the transformed cell lines obtained in Example 6, and genotyping PCR was performed to determine whether the gene was inserted.
[0137] Specifically, genotyping PCR was performed by extracting genomic DNA from cells using the DNeasy Blood & Tissue kit (#69506, Qiagen) according to the manufacturer's manual. Genotyping PCR was performed using the extracted genomic DNA and ExPrime Taq Premix (2X, 8-strip) (#G-6000, GeNet Bio) under the conditions listed in Table 6 above.
[0138] In-Fusion PCR Temperature Time Step 1: 95℃ 5 minutes Step 2: 35 cycles 95℃ 62℃ 72℃ 30 seconds 30 seconds 30 seconds Step 3: 72℃ 5 minutes Step 1: Initial denaturation, Step 2: Amplification, Step 3: Final elongation
[0139] The samples for genotyping PCR were electrophoresed on a 0.8% agarose gel prepared using Agarose, LE, Analytical Grade (#V3125, Promega) and 0.5X TAE (50X TAE; TR2002-100-00, Biosesang, diluted to 0.5X with 3-stage water) at 120 V for 30 minutes. After that, the band sizes of the samples were compared to distinguish wild-type, heterotype, and homotype cells. PCR primers for amplification of genomic DNA were designed in silico using Primer3 software (https: / / bioinfo.ut.ee / primer3-0.4.0 / ), and are shown in Figure 18 and Table 7 below. Figure 19 shows the electrophoresis results, and #1 to #16 of Figure 19 show cells in which EGFP fluorescence is expressed and maintained through a fluorescence microscope among the transformed cell lines obtained in Example 6.
[0140] Primer bp sequence sequence number AAVS1 endo F339bpCCCCTATGTCCACTTCAGGA19AAVS1 endo R339bpAGGATCCTCTCTGGCTCCAT20AAVS1-EGFP KI R686bpGTTCACCTTGATGCCGTTCT21
[0141] As a result, as shown in Fig. 19, in the case of HEK293 cells in which the AAVS1-EGFP #4 vector was not inserted (knock-in; KI) (WT), a 339 bp PCR product appeared, in the case of the heterozygote with the insertion in one allele (#2 to #7, #9 to #16), 339 bp and 686 bp PCR products were observed, and in the case of the homozygote (#8), only the 686 bp PCR product was observed.
[0142] Example 8. Confirmation of fluorescence expression in transformed cell lines
[0143] Among the HEK293 cells inserted with the AAVS1-EGFP #4 vector verified in Example 7, the heterozygous #3 cells and the homozygous #8 cells were treated with Staurosporin (STA), an apoptosis-inducing substance, for 48 hours, and the fluorescence changes were confirmed through fluorescence microscopy and flow cytometry, which are shown in Figs. 20 and 21, respectively.
[0144] As a result, it was confirmed through fluorescence microscopy that fluorescence decreased in both the heterozygous type with insertion in one allele and the homozygous type with insertion in both alleles when treated with 1 μM concentration of staurosporine for 48 hours. In addition, it was confirmed that fluorescence was expressed more strongly in the homozygous type with insertion in both alleles than in the heterozygous type with insertion (Fig. 20).
[0145] Furthermore, as shown in Figure 21, flow cytometry analysis confirmed that fluorescence decreased in real time when treated with staurosporine for 48 hours compared to 24 hours in both heterozygous cells inserted in one allele and homozygous cells inserted in both alleles. Furthermore, it was confirmed that real-time fluorescence changes were better observed in homozygous cells inserted in both alleles compared to heterozygous cells inserted in one allele.
[0146] Through this, it was confirmed that stronger fluorescence expression could be induced by inserting the AAVS1-EGFP #4 vector into both alleles, and it was possible to observe fluorescence changes due to apoptosis in real time through HEK293 cells inserted with the AAVS1-EGFP #4 vector.
[0147] Example 9. Confirmation of mRNA expression level in transformed cell lines
[0148] In Example 7, HEK293 cells inserted with the AAVS1-EGFP #4 vector were treated with staurosporine, an apoptosis-inducing substance, for 48 hours, and the level of mRNA expression of the green fluorescent protein variant was confirmed through Semi RT-PCR (Semiquantitative RT-PCR).
[0149] Specifically, HEK293 wild-type cells (WT) without AAVS1-EGFP #4 vector insertion, #3 cells of AAVS1-EGFP #4 heterogeneous type and #8 cells of AAVS1-EGFP #4 homogeneous type among the HEK293 cells with AAVS1-EGFP #4 vector insertion verified in Example 7 were treated with staurosporine for 48 hours.
[0150] Afterwards, total RNA was extracted from the cells using the RNeasy plus mini kit (#74136, Qiagen) according to the manufacturer's manual. The extracted total RNA (1 μg) was synthesized into cDNA using the PrimeScript RT reagent kit with gDNA Eraser (# RR047A, Takara Bio Inc) according to the manufacturer's manual. Using the cDNA as a template, genotyping PCR was performed using ExPrime Taq Premix (2X, 8-strip) (#G-6000, GeNet Bio) under the conditions shown in Table 8 below.
[0151] Semi-RT PCR Temperature Time Step 1: 95℃ 5 minutes Step 2: 35 cycles 95℃ 62℃ 72℃ 30 seconds 30 seconds 30 seconds Step 3: 72℃ 5 minutes Step 1: Initial denaturation, Step 2: Amplification, Step 3: Final elongation
[0152] The samples for genotyping PCR were electrophoresed on a 1.0% agarose gel prepared using Agarose, LE, Analytical Grade (#V3125, Promega) and 0.5X TAE (50X TAE; TR2002-100-00, Biosesang, diluted to 0.5X with 3-stage water) at 120 V for 30 minutes. The sample bands were then compared to determine the level of mRNA expression. PCR primers for amplification of genomic DNA were designed in silico using Primer3 software (https: / / bioinfo.ut.ee / primer3-0.4.0 / ) and are shown in Table 9 below.
[0153] Primer bp sequence Sequence number EGFP semi-RT PCR F245bp AGAAGAACGGCATCAAGGTG22 EGFP semi-RT PCR R245bp CTGTACAGCTCGTCCATGC23 GAPDH semi-RT PCR F131bp GAGCCACATCGCTCAGACAC24 GAPDH semi-RT PCR R131bp AAGGGGTCATTGATGGCAAC25
[0154] As a result, it was confirmed through Semi RT-PCR that when staurosporine was treated for 24 and 48 hours, fluorescence decreased in real time, while the expression level of green fluorescent protein mutant mRNA did not change (Fig. 22).
[0155] Through this, it was confirmed that the fluorescence change in HEK293 cells inserted with AAVS1-EGFP #4 vector was due to truncation of the DEVDG sequence of the green fluorescent protein variant.
[0156] Experimental Example 10. Measurement of cell damage in transformed cell lines and confirmation of fluorescence expression and expression of cell damage-related proteins.
[0157] In Example 7, #8 cells of the AAVS1-EGFP #4 homo genotype described in Example 7 were treated with staurosporine, an apoptosis-inducing substance, at concentrations of 0.1 μM, 0.25 μM, 0.5 μM, and 1 μM for 48 hours, and then the fluorescence expression of the green fluorescent protein variant was confirmed through fluorescence microscopy and flow cytometry, and the expression levels of cell damage-related genes such as Caspase 3, Cleaved Caspase 3, Cytochrome C, PARP, and Cleaved PARP were confirmed through Western blot.
[0158] Specifically, Western blot was performed as follows: 30 to 60 μg of protein lysates were separated on 8 to 12% sodium dodecyl sulfate-polyacrylamide gels by SDS-PAGE and then transferred to 0.45 μm nitrocellulose membranes (Cat # HAWP04700, EMD Millipore, Burlington, MA, USA).
[0159] The membranes were immersed in a solution containing 10 mM Tris pH 7.4, 150 mM NaCl and 0.02% Tween-20 (TBST), blocked with 5% skim milk (Cat # 232100, BD Biosciences) or bovine serum albumin (Cat # A9647, Sigma-Aldrich), and then incubated with primary antibodies (GFP, Cat #50430-2-AP, Proteintech, 1:2000; Caspase 3, Cat #9662S, Cell signaling technology, 1:1000; Cleaved Caspase-3, Cat #9664L, Cell signaling technology, 1:1000; Cytochrome C, Cat #4280S, Cell signaling technology, 1:1000; PARP, Cat #9532S, Cell signaling technology, 1:1000; Cleaved PARP, Cat #5625S, Cell signaling technology, 1:1000; GAPDH, Cat #LF-MA0038, AB Frontier, 1:2000) were incubated overnight at 4°C.
[0160] The membrane was then washed three times with TBST, reblocked with 5% skim milk, and incubated with horseradish peroxidase-conjugated secondary antibody for 1 hour at room temperature. After incubation, the blot was washed with TBST, and antibody binding was confirmed using SuperSignal West Pico PLUS Chemiluminescent Substrate (Cat # 34580, Thermo Fisher Scientific) according to the manufacturer's instructions.
[0161] As a result, it was confirmed that the expression of green fluorescent protein decreased in #8 cells of the AAVS1-EGFP #4 homo genotype as the treatment concentration of staurosporine increased (Figs. 23 and 24).
[0162] Additionally, as shown in Figure 25, it was confirmed that as the treatment concentration of staurosporine increased, the expression of cell damage-related proteins such as Cleaved Caspase 3, Cytochrome C, and Cleaved PARP also increased.
[0163] Through this, it was confirmed that the change in the expression of green fluorescent protein in #8 cells of the AAVS1-EGFP #4 homo genotype was due to the expression of a cell damage-related protein.
[0164] Experimental Example 11. Fluorescence expression and cell damage in transformed cell lines.
[0165] After treating #8 cells of the AAVS1-EGFP #4 homo genotype described in Example 7 with staurosporine, an apoptosis-inducing substance, DNA damage, one of the characteristics of apoptosis, was observed using fluorescent dyes TUNEL (Terminal deoxynucleotidyl transferase dUTP nick end labeling) and DAPI staining, and through this, fluorescence expression and the degree of cell damage in the transformed cell line were confirmed.
[0166] Specifically, apoptosis was confirmed in #8 cells of AAVS1-EGFP #4 homo genotype treated with staurosporine using the in situ cell death detection kit, POD (Roche, Germany) using the TUNEL method.
[0167] First, #8 cells of AAVS1-EGFP #4 homogenous genotype were seeded in the medium and cultured for 24 hours, and then treated with staurosporine at concentrations of 0.5 μM and 1 μM for 48 hours and cultured for 48 hours.
[0168] Afterwards, 4% paraformaldehyde was added and fixed for 30 minutes at room temperature, washed three times with PBS, and treated with a permeabilization solution containing 0.1% Triton X-100 for 10 minutes. After washing three more times with PBS, terminal deoxynucleotidyl transferase (TDT) and nucleotide mixture were added, and incubated at 37°C for 1 hour while blocking light.
[0169] After washing twice with PBS, the cultured cells were observed under a fluorescence microscope to confirm apoptosis. At this time, 4,6-diamino-2-phenylindole (DAPI, Sigma) solution was used for control staining of cells that did not undergo apoptosis.
[0170] As a result, as shown in Fig. 26, it was confirmed that DNA damage increased in cells in which green fluorescence decreased due to staurosporine treatment, leading to an increase in TUNEL fluorescence.
[0171] Example 12. Confirmation of the location of target sequence #4 of blue fluorescent protein, yellow fluorescent protein, and cyan fluorescent protein.
[0172] To confirm that target sequence #4 exists at the same position in the cyan, yellow, and cyan fluorescent proteins derived from green fluorescent protein, the base sequences of each fluorescent protein were analyzed. The fluorescent proteins derived from green fluorescent protein all have similar structures, and it is known that some base sequences encoding green fluorescent protein differ, resulting in different colors of fluorescence.
[0173] As a result, it was confirmed that the target sequence #4 was present at the same position as the enhanced green fluorescent protein in the enhanced blue fluorescent protein (EBFP), enhanced yellow fluorescent protein (EYFP), and enhanced cyan fluorescent protein (ECFP) (Fig. 27). The position of the target sequence #4 in each base sequence encoding EBFP, EYFP, and ECFP is shown in Figs. 28 to 30.
[0174] Through this, it was determined that since the position of target sequence #4 is the same in EBFP, EYFP, and ECFP as in EGFP, even if target sequence #4 is mutated to a base sequence encoding DEVDG, the function of the fluorescent protein is not affected.
[0175] Example 13. Construction of a pCAGGS vector containing a gene encoding a blue fluorescent protein variant.
[0176] In the same manner as in Example 2, the target sequence #4 of the wild-type enhanced cyan fluorescent protein (EBFP) was mutated to the GACGAGGTGGACGGC base sequence (SEQ ID NO: 12) so that the amino acid sequence encoded by this base sequence became DEVDG (SEQ ID NO: 13).
[0177] Thereafter, using the same method as Example 3, the wild-type EBFP and the EBFP mutant genes with a mutation at position #4 were each cloned into the pCAGGS vector. Since the base sequences preceding and following the target sequence #4 of EGFP and EBFP are identical, the same in-fusion PCR conditions and primers as those for the EGFP experiment in Example 3 were used. The individually prepared pCAGGS vectors are shown in Figures 31 and 32.
[0178] HIT Competent Cells-DH5alpha High 108 (#RH618, RBC) were transformed with pCAGGS vectors each containing the wild-type EBFP and mutant genes in LB broth plates.
[0179] Example 14. Confirmation of fluorescence expression of blue fluorescent protein variants
[0180] Expression of the blue fluorescent protein mutant of the pCAGGS vector prepared in Example 13 was confirmed.
[0181] As a result of confirming the expression of the blue fluorescent protein mutant in the cell line into which the pCAGGS vector was introduced through a fluorescence microscope, it was confirmed that the genetically mutant blue fluorescent protein was expressed normally in the cell line into which pCAGGS containing the EBFP #4 mutant gene was introduced (Fig. 33).
[0182] Through this, it was confirmed that other fluorescent proteins that have a base sequence region that matches the target sequence #4 of EGFP (consensus) can also express fluorescence in the same way as the green fluorescent protein mutant even when the target sequence #4 is mutated to a gene encoding DEVDG, and thus can be used to confirm the activity of caspases 3 and 7.
[0183] Therefore, not only green fluorescent protein mutants but also mutants of fluorescent proteins of other colors can be used to observe fluorescence changes due to apoptosis in real time.
[0184] Example 15. Confirmation of real-time cell damage monitoring - Live imaging
[0185] AAVS1-EGFP #4-8 (homo) genotype 293 cell line was cultured in Dulbecco's Modified Eagle's Medium (DMEM, #11995, ThermoFisher) supplemented with 10% fetal bovine serum (FBS; #16000, ThermoFisher) and 1% penicillin / streptomycin (#15140, ThermoFisher) in a 5% CO2, 37°C incubator. 5 x 10 cells were seeded in a 100 mm dish when the cells were 60-70% confluent. 4 / well cells were subcultured onto Lab-Tek™ II chamber slide™ (#154526PK, Nunc). After 2 days, staurosporine (STA) was treated at a concentration of 1 μM, and fluorescence was observed at 30-minute intervals for 48 h using a fluorescence microscope (Leica) equipped with a live cell imaging system.
[0186] After inducing apoptosis in 293 AAVS1-EGFP #4-8 cells (STA treatment), fluorescence was observed at 30-minute intervals for 48 hours, and a decrease in fluorescence over time was observed (Fig. 38A). In contrast, in the control group (staurosporine-untreated; -STA), fluorescence increased over time, and this increase in fluorescence is believed to be due to cell proliferation (Fig. 38B). Therefore, it was confirmed that the reporter system of the present invention is also suitable for real-time monitoring.
[0187] Example 16. Construction of a transformed colon cancer cell line introducing the AAVS1-EGFP #4 vector.
[0188] The AAVS1 SA-EGFP #4 vector prepared in Example 5 was introduced into colon cancer cell lines SW480, SW620, and HCT 116 purchased from ATCC, respectively, to establish transformed cell lines as in Example 6. The cell lines were cultured in a 5% CO2, 37°C incubator using Dulbecco's Modified Eagle's Medium (DMEM, #11995, ThermoFisher) supplemented with 10% fetal bovine serum (FBS; Fetal Bovine Serum, #16000, ThermoFisher) and 1% penicillin / streptomycin (#15140, ThermoFisher).
[0189] First, SW480, SW620, and HCT 116 cells were cultured in 100 mm dishes. When the cells were 70% to 80% confluent, 5 μg of AAVS1-EGFP #4 vector was introduced into the cells using Lipofectamine 3000 according to the manufacturer's manual. Then, when the cells were 90% confluent, 3 μl of puromycin (#A11138-03, gibco) was added to 10 ml of culture medium to perform puromycin selection. After 14 days, when the cells were again 70% to 80% confluent, cells expressing green fluorescent protein were selected for the second time using fluorescence-activated cell sorting (FACS). The selected single cells were then seeded in 96-well plates, cultured, and subcultured to 24-well plates to establish transformed cell lines.
[0190] To confirm that the AAVS1-EGFP #4 vector was correctly inserted into the colon cancer cell lines SW480, SW620, and HCT 116, the genotyping test used in Example 7 was performed.
[0191] As a result, it was confirmed that cell lines stably expressing fluorescent protein variants were constructed using the AAVS1-EGFP #4 vector system used in the present invention in each of the colon cancer cell lines SW480, SW620, and HCT 116, and hetero and homo cell lines were confirmed through genotyping analysis (Figs. 39 to 41).
[0192] Example 17. Verification of cell damage reporter ability of a transformed colon cancer cell line introduced with the AAVS1-EGFP #4 vector.
[0193] To verify the cell damage reporter ability, the AAVS1-EGFP #4 expressing colon cancer cell lines SW480 and SW620 constructed in Example 16 were treated with 1 μM concentration of staurosporine (STA), and the fluorescence changes were checked after 24 and 48 hours to confirm whether the reporter was functioning.
[0194] As a result, it was confirmed that fluorescence decreased when cell damage occurred when treated with staurosporine (STA) compared to the control group (staurosporine untreated; -STA) (Figs. 42 and 43).
[0195] Comparative Example 1. Confirmation of non-uniform fluorescence expression in a transformed cell line introduced with the pCAGGS-EGFP #4 vector.
[0196] The EGFP #4 mutant gene was cloned into the pCAGGS vector to produce the pCAGGS-EGFP #4 vector, which was then introduced into HEK293 cells derived from human embryonic kidney, and the level of fluorescence expression was confirmed.
[0197] First, HEK293 cells were seeded on a 100 mm culture dish, and when the cells were cultured to about 70% to 80% confluent, 5 ㎍ of pCAGGS-EGFP #4 vector was introduced into the cells using a 4D-Nucleofector™ device according to the SF kit, CM-130 program, and the manufacturer's manual.
[0198] Subsequently, expression of green fluorescent protein mutants in cell lines introduced with each pCAGGS-EGFP #4 vector was confirmed using fluorescence microscopy and flow cytometry.
[0199] As a result, as shown in FIGS. 34 and 35, it was confirmed that the green fluorescent protein mutant was expressed normally but unevenly in the cell line into which the pCAGGS-EGFP #4 vector was introduced.
[0200] Through this, it was confirmed that there are many cells that quantitatively express fluorescence unevenly in the cell line introduced with the pCAGGS-EGFP #4 vector, and that it is difficult to uniformly express the green fluorescent protein mutant when using the pCAGGS vector.
[0201] Comparative Example 2. Confirmation of the level of fluorescence expression in a transformed cell line introduced with the pCAGFP vector.
[0202] A green fluorescent protein mutant was prepared by inserting a caspase recognition sequence (DEVD) between the green fluorescent protein and the quenching peptide (QP) sequence, and the mutant gene was cloned into a Caspase Activatable-GFP (CA-GFP) (pCAGFP #32748, Addgene) vector to prepare a vector system in which fluorescence is expressed when the green fluorescent protein mutant is cleaved by caspase 3 or caspase 7 (J Biol Chem. 2011 Jul 15;286(28):24977-86).
[0203] After introducing the manufactured vector into HEK293 cells derived from human embryonic kidney, the change in fluorescence expression was confirmed by treating with staurosporine at a concentration of 1 μM.
[0204] Specifically, after HEK293 cells were seeded on a 100 mm culture dish, when the cells were cultured to about 70% to 80% confluent, 5 μg of pCAGFP vector was introduced into the cells using a 4D-Nucleofector™ device according to the SF kit, CM-130 program, and the manufacturer's manual.
[0205] After staurosporine treatment in cell lines introducing the pCAGFP vector, expression of the green fluorescent protein mutant was confirmed through fluorescence microscopy and flow cytometry.
[0206] As a result, as shown in Figures 36 and 37, it was confirmed that green fluorescence expression increased after treatment with 1 μM staurosporine in a cell line into which the pCAGFP vector was introduced, but fluorescence was not uniformly observed in all cells, and it was confirmed that fluorescence was already strongly expressed before treatment with staurosporine in some cell lines.
[0207] Through this, it was confirmed that it is difficult to accurately determine the presence or absence of cell damage due to fluorescence expression in the above vector system.
Claims
1. A fluorescent protein (FP) mutant whose fluorescence expression changes in damaged or dead cells. A fluorescent protein variant comprising an amino acid sequence that is cleaved by a caspase in the hinge region of the fluorescent protein variant, which does not affect the function of the fluorescent protein.
2. In paragraph 1, The fluorescent protein is a fluorescent protein variant, wherein the fluorescent protein is Green Fluorescent Protein (GFP), Blue Fluorescent Protein (BFP), Yellow Fluorescent Protein (YFP), or Cyan Fluorescent Protein (CFP).
3. In paragraph 1, A fluorescent protein variant wherein the amino acid sequence cleaved by the above caspase is aspartic acid-glutamic acid-valine-aspartic acid-glycine (DEVDG) or aspartic acid-glutamic acid-valine-aspartic acid (DEVD).
4. In paragraph 1, The fluorescent protein variant is a fluorescent protein variant in which the asparagine-isoleucine-glutamic acid (NIE) sequence in the amino acid sequence of the fluorescent protein before mutation is replaced with the aspartic acid-glutamic acid-valine (DEV) sequence.
5. In paragraph 4, A fluorescent protein variant wherein the above asparagine-isoleucine-glutamic acid (NIE) sequence is the 171st to 173rd amino acid of the amino acid sequence represented by SEQ ID NO: 1, the 171st to 173rd amino acid of the amino acid sequence represented by SEQ ID NO: 33, the 172nd to 174th amino acid of the amino acid sequence represented by SEQ ID NO: 34, or the 171st to 173rd amino acid of the amino acid sequence represented by SEQ ID NO:
35.
6. In paragraph 1, The above caspase is a fluorescent protein variant, which is caspase 3 or caspase 7.
7. A polynucleotide encoding the fluorescent protein variant of paragraph 1.
8. A recombinant vector comprising the polynucleotide of paragraph 7.
9. In paragraph 8, A recombinant vector wherein the above vector is an AAVS1 (adeno-associated virus integration site 1) vector.
10. In paragraph 8, A recombinant vector wherein the polynucleotide is a nucleotide sequence represented by SEQ ID NO: 14, a nucleotide sequence represented by SEQ ID NO: 39, a nucleotide sequence represented by SEQ ID NO: 40, or a nucleotide sequence represented by SEQ ID NO:
41.
11. A composition for detecting cell damage or apoptosis, comprising the fluorescent protein variant of paragraph 1, the polynucleotide of paragraph 7, or the recombinant vector of paragraph 8 as an active ingredient.
12. A transformed cell transformed with the recombinant vector of Article 8. 13.i) Step of treating a sample with the transformed cell of clause 12; ii) a step of measuring the fluorescence expression of cells treated with the above sample; and iii) A method for evaluating drug toxicity, comprising a step of determining that the sample is toxic to cells when fluorescence expression changes.
14. In paragraph 13, A method for evaluating drug toxicity, wherein the change in fluorescence expression in step iii) above is due to the activity of caspase 3 or caspase 7.
Citation Information
Patent Citations
The apoptosis sensing cell and the detection method ofapoptosis using the same
KR1020080008072A
GFP-based constructs and methods for detecting apoptosis
US20040002128A1
Enhanced inserted yellow fluorescence protein and its application
US20050170428A1
Modified fluorescent proteins for detecting protease activity
US7049400B1
Assays for caspase activity using green fluorescent proteins
WO2000073437A1
